Published in Circ Arrhythm Electrophysiol on December 01, 2009
Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia in patients with an implantable defibrillator warrants catheter ablation. Circ Arrhythm Electrophysiol (2009) 0.80
Current and emerging antiarrhythmic drug therapy for ventricular tachycardia. Cardiol Ther (2013) 0.76
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
J wave syndromes. Heart Rhythm (2009) 3.54
Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest (2013) 2.42
Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol (2009) 2.16
T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol (2008) 2.14
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out. Am J Med (2012) 2.08
Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. Am Heart J (2013) 2.05
Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm (2006) 2.03
Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation (2002) 1.84
Ventricular repolarization components on the electrocardiogram: cellular basis and clinical significance. J Am Coll Cardiol (2003) 1.81
The diagnosis of cardiac arrhythmias: a prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring. J Cardiovasc Electrophysiol (2007) 1.77
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J (2011) 1.72
Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J (2009) 1.66
L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation. J Cardiovasc Electrophysiol (2006) 1.57
Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. Circulation (2004) 1.57
L-type calcium current recovery versus ventricular repolarization: preserved membrane-stabilizing mechanism for different QT intervals across species. Heart Rhythm (2007) 1.48
Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: a blinded validation. Heart Rhythm (2012) 1.44
Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm (2007) 1.23
Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol (2010) 1.21
The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol (2009) 1.21
Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist (2013) 1.19
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc (2013) 1.15
Dronedarone. Circulation (2009) 1.14
Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry). Am J Cardiol (2010) 1.11
ST-segment elevation in the early repolarization syndrome, idiopathic ventricular fibrillation, and the Brugada syndrome: cellular and clinical linkage. J Electrocardiol (2005) 1.10
The QT and Tp-e intervals in left and right chest leads: comparison between patients with systemic and pulmonary hypertension. J Electrocardiol (2005) 1.06
Electrical failure of an ICD lead due to a presumed insulation defect only diagnosed by a maximum output shock. Pacing Clin Electrophysiol (2013) 1.06
Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers. Br J Pharmacol (2010) 1.05
In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob Agents Chemother (2012) 1.02
ECG repolarization waves: their genesis and clinical implications. Ann Noninvasive Electrocardiol (2005) 1.02
Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J (2012) 1.01
Ventricular transmural repolarization sequence: its relationship with ventricular relaxation and role in ventricular diastolic function. Eur Heart J (2009) 0.99
First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. Am J Cardiol (2005) 0.99
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes (2013) 0.97
Calcium-activated chloride current contributes to action potential alternations in left ventricular hypertrophy rabbit. Am J Physiol Heart Circ Physiol (2008) 0.96
Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol (2011) 0.96
Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation. Pharmacol Ther (2008) 0.95
A novel mutation in the KCNH2 gene associated with short QT syndrome. J Mol Cell Cardiol (2010) 0.94
Mechanisms underlying arrhythmogenesis in long QT syndrome. J Electrocardiol (2005) 0.94
Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol (2006) 0.94
Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. J Electrocardiol (2004) 0.93
J-wave syndromes. from cell to bedside. J Electrocardiol (2011) 0.93
Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm (2008) 0.92
Modulation of the late sodium current by ATX-II and ranolazine affects the reverse use-dependence and proarrhythmic liability of IKr blockade. Br J Pharmacol (2011) 0.92
Contribution of late sodium current (I(Na-L)) to rate adaptation of ventricular repolarization and reverse use-dependence of QT-prolonging agents. Heart Rhythm (2010) 0.92
Rationale for the use of the terms J-wave syndromes and early repolarization. J Am Coll Cardiol (2011) 0.91
Wenxin Keli suppresses ventricular triggered arrhythmias via selective inhibition of late sodium current. Pacing Clin Electrophysiol (2013) 0.90
PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects. Eur J Pharmacol (2009) 0.89
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol (2005) 0.88
Fast-track training of nonelectrophysiologists to implant defibrillators: is it needed? Pacing Clin Electrophysiol (2006) 0.87
A rare cause of 2:1 AV block: long QT syndrome. J Cardiovasc Electrophysiol (2008) 0.87
A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs). J Pharmacol Toxicol Methods (2013) 0.87
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J (2013) 0.86
Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J (2009) 0.86
Vanoxerine: cellular mechanism of a new antiarrhythmic. J Cardiovasc Electrophysiol (2009) 0.86
Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. Am J Med (2013) 0.86
Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol (2008) 0.85
Increasing I(Ks) corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy. Am J Physiol Heart Circ Physiol (2002) 0.83
The electrocardiographic manifestations of arrhythmogenic right ventricular dysplasia. Curr Cardiol Rev (2014) 0.83
Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in timothy syndrome. Circ Arrhythm Electrophysiol (2013) 0.83
Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J Cardiovasc Electrophysiol (2005) 0.82
Role of signal-averaged electrocardiograms in arrhythmic risk stratification of patients with Brugada syndrome: a prospective study. Heart Rhythm (2009) 0.82
The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis (2004) 0.81
Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans. Clin Exp Pharmacol Physiol (2012) 0.81
Bioequivalence of 2 intravenous amiodarone formulations in healthy participants. J Clin Pharmacol (2009) 0.80
Increased late sodium current in left atrial myocytes of rabbits with left ventricular hypertrophy: its role in the genesis of atrial arrhythmias. Am J Physiol Heart Circ Physiol (2010) 0.80
Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogs. Cardiovasc Toxicol (2009) 0.80
Case of polymorphic ventricular tachycardia in diphenhydramine poisoning. J Cardiovasc Electrophysiol (2004) 0.80
Proarrhythmias and antiarrhythmias: two sides of the same coin. Heart Rhythm (2005) 0.79
Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans. Am J Cardiol (2009) 0.79
Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies. Curr Opin Cardiol (2006) 0.78
The funny current (If): is it a novel antiarrhythmic target to treat atrial fibrillation? J Cardiovasc Electrophysiol (2011) 0.78
Stroke prevention in atrial fibrillation. J Cardiovasc Med (Hagerstown) (2012) 0.78
Electrocardiographic T wave: a symbol of transmural dispersion of repolarization in the ventricles. J Cardiovasc Electrophysiol (2003) 0.78
L539 fs/47, a truncated mutation of human ether-a-go-go-related gene (hERG), decreases hERG ion channel currents in HEK 293 cells. Clin Exp Pharmacol Physiol (2013) 0.78
Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol (2003) 0.77
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? Am J Cardiol (2008) 0.77
Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm (2011) 0.76